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Abstract
Background. Metoclopramide is a pharmacological agent frequently used in therapy against
nausea and vomiting that can occur in indigestion, motion sickness, gastric ulcer, pyloric spasm and
after surgery as a side effect of some anesthetics. Knowing the frequency and intensity of
metoclopramide neurological side effects is essential for an efficient management of the dysfunctions it
addresses.
Material and method. Based on a standard questionnaire containing questions regarding
metoclopramide therapy, we analyzed the answers given by 1000 patients or patient tutors in 20 open
circuit pharmacies situated all over Bucharest. All subjects freely consented to participate in this study
that was coordinated only by pharmacists.
Results. Our study highlights the fact that in certain situations having to do with the age of
patients, with the use of multiple drugs or with the tendency to self medicate, the neurological side
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effects of metoclopramide can reach dangerous levels. In some cases it might even be necessary to
immediately interrupt metoclopramide therapy, despite its positive benefit/ risk ratio.
Conclusions. Respecting the physician’s recommendations, avoiding self medication and
reporting side effects as quickly as possible, are essential elements for minimizing the consequences of
metoclopramide side effects.
Introduction
Metoclopramide is an antiemetic and gastro-prokinetic agent working as a dopaminergic
antagonist, currently under close survey by the European Medicines Agency due to its acute and chronic
neurological side effects. The Metoclopramide molecule was first described by Besancon and Laville in
1964 and by the end of 1982 it was already available in generic form (1). Since then, the scientific
literature has recorded extrapyramidal phenomena as the main side effects of metoclopramide. They
consist in dystonia (opistotonus, torticollis, trismus, dysarthria, oculogyric crisis), akathisia,
parkinsonism, tardive dyskinesia and can occur both in high and in usual doses. The incidence of
extrapyramidal side effects after metoclopramide use is generally 0.2%, but it can reach up to 25% in
elderly patients and teenagers. In children, the risk of this type of side effect occurring is 6 times higher
than it is in adults. Tardive dyskinesia and parkinsonism are known to appear only after chronic use
while dystonia and akathisia can occur even after a single dose of metoclopramide. The main
predisposing factors that favor neurological side effects are: high doses, long term treatment and use of
metoclopramide in children and elderly patients. A detailed anamnesis before initiating metoclopramide
therapy is necessary in order to avoid wrong diagnostics and inappropriate management of neurological
side effects (2, 3).
The clinical manifestations of extrapyramidal symptoms such as dystonia, akathisia,
parkinsonism and dyskinesia include an atypical number of involuntary muscle contractions that affect
posture, movement and walking (4). The cause of this type of phenomena is most likely the blockage of
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dopamine transmission in various CNS structures. Extrapyramidal symptoms generated by some
antipsychotic drugs may also be associated with some other pharmacological agents such as antiemetics,
antidepressants, oral antidiabetics, lithium, antiepileptics, and contraceptives (5). The goal of the current
study is on one hand to underline the importance of pharmacovigilence in identifying and quantifying
foreseeable (dose dependent) side effects and unforeseeable (dose independent) side effects (6) and on
the other hand to compare our results to what medical literature describes regarding the neurological side
effects of metoclopramide.

Materials and Methods
1000 patients or tutors of patients were questioned regarding the pathological context that
prompted the initiation of metoclopramide therapy and the neurological side effects experienced under
these circumstances. The study was conducted in 20 open circuit pharmacies between March of 2014
and June of the same year. Only pharmacists asked the questions, noted the answers and explained the
medical terminology to the patients.
Inclusion criteria were as follow: Age of patients between 12 and 80 years old, maximum 2
additional illnesses or associated co-morbidities (patients with major decompensated neurological
conditions were not enlisted in this study), absence of
known conditions that reduce the activity of organs
involved in drug biotransformation and elimination (liver
and/or kidney)
Statistics.

The

statistical

calculus

of

the

percentages expressing the results of our study was done
using Microsoft Excel 2003 software.
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Results
After the centralization of all date we report the
following results: the sex distribution of the subjects
showed that 58.4% of the patients were female and
41.6% were male. Taking into account the age criteria,
26.8% were between 12 and 30 years old, 40,6%
between 30 and 55 years old and 32,6% between 55
and 80 years old. Metoclopramide therapy was initiated
based on a written medical prescription in 67,5% of
cases, based on the physician’s verbal recommendation
in 14.3% of cases, based on the pharmacist’s
recommendation in 10.4% of cases, based on patient`s
owns initiative in 3.6% of cases and based on the
recommendation of unauthorized persons in 4.2% of
cases.
The diagnostic that prompted the initiation of
metoclopramide therapy was indigestion in 60.4% of
cases, gastric ulcer in 24.7% of cases, pyloric spasm in
8.9% of cases, motion sickness in 4% of cases and post
anesthetic sickness in 2% of cases. 57.6% of all patients
reported using other drugs while being under
metoclopramide therapy. 32.64% of them (188
individuals) reported using omeprazole, 15.97% (92
individuals) reported using indapamide, 12.67% (73
58
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individuals) reported using drotaverine, and 9.55% (55 individuals) reported using perindopril and
29.17% (168 individuals) reported using other drugs.
Regarding side effects, 74.6% of patients
reported no side effects what so ever, 14.2% reported
sleepiness and confusion, 6.3% reported depression,
2.8% reported tremors and uncontrolled movements,
1.3% reported muscle rigidity and 0.8% reported
hallucinations and altered states of conscience. Out of
the 254 patients that did report side effects, 69.69%
reported experiencing them in the first 12 hours,
20.87% felt them between 12 and 48 hours after
initiating metoclopramide therapy and in 9.49% of
cases, the side effects occurred more than 48 hours
after the first dose of metoclopramide. Regarding side
effect intensity, 72.83% of patients (185 individuals)
considered them as having a low intensity, 15.75%
(40 individuals) rated the side effects as being
moderate and 11.42% (29 individuals) felt them with
severe intensity.
Analyzing the age of patients that reported
side

effects

we

observed

that

42.51%

(108

individuals) were between 12 and 30 years old,
25.98% (66 individuals) were between 30 and 55
years old and 31.51% (80 individuals) were between 55 and 80 years old.
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Out of the 254 patients that reported side effects after using metoclopramide, 38.98% (99
individuals) were also under treatment with omeprazole. Analyzing compliance, we observed a higher
tendency to noncompliance, especially by reducing
the interval between doses and by increasing
prescribed doses in patients below the age of 30. This
observation can be correlated with the higher
incidence of side effects reported by this age group.
Analyzing the individual cases of patients that
reported moderate and severe side effects we noted
the following particular situations:
 5 patients were under treatment with selective
inhibitors of serotonin recapture (2 with fluoxetine
100mg/day and 3 with paroxetine 20mg/day) when
they started administering metoclopramide and
reported

agitation,

hyperexcitability,

tremors,

hyperthermia and intense sweating
 7 patients were under treatment with first generation antihistaminic drugs (5 with cyproheptadine
4mg/day and 2 with chlorpheniramine 8mg/day) when they started administering metoclopramide and
reported intense daytime sleepiness, lack of motor coordination and inability to perform precision
requiring activities
 4 patients were under treatment with antidopaminergic neuroleptics (2 with haloperidol 2mg/day and 2
with chlorpromazine 10mg/day) when they started administering metoclopramide and reported
involuntary movement of neck and tongue muscles, rigidity in extremities, hyperthermia and
hallucinations
60
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 2 epileptic patients under treatment with carbamazepine (400mg/day) reported an epileptic seizure more
intense than usual in the first 12 to 36 hours after initiating metoclopramide therapy
Discussion
Metoclopramide is the first choice antiemetic for treating nausea due to intestinal disorders,
hepatic or gall dysfunctions, but it can also be used to some extent in nausea and vomiting induced by
radiotherapy, chemotherapy, Ménière syndrome and motion sickness. Metoclopramide is also a
gastroprokinetic drug due to its peripheral cholinergic mechanism and is used in gastrointestinal reflux
and pyloric spasm because it increases the tonus of the Cardia sphincter, it relaxes the pyloric sphincter,
it speeds up the emptying of the stomach, it improves intestinal transit and it enhances the peristaltic
movement of the esophagus, the stomach and intestines (6, 7). Metoclopramide has two main types of
mechanisms that explain on one hand the therapeutic effects (antiemetic, gastroprokinetic) and on the
other hand, the neurological side effects (sleepiness, anxiety, depression, dystonia, akathisia,
parkinsonism, dyskinesia) and the abdominal side effects (diarrhea, constipation, flatulence):


D2 dopaminergic receptors antagonist both on a central level in the rachidian bulb and in the triggering
chemoreceptor area and on a peripheral level in the gastrointestinal tract; by exacerbating the D2
blockage, extrapyramidal effects manifest themselves especially in children, teenagers and elderly
patients. They consist in dystonic movements of the face, tongue and limbs, tetanic spasm, torticollis,
trismus, tardive dyskinesia and akathisia. Another antidopaminergic related side effect is
hyperprolactinemia often associated with diminished libido, gynecomastia, galactorrhea and
amenorrhea.



Cholinergic effect by releasing acetylcholine in the digestive neuroeffector junctions, thus accelerating
the emptying of the stomach and improving intestinal transit; exacerbating the cholinergic mechanisms
leads to symptoms such as diarrhea and abdominal pain (6, 8).
Medical literature describes the following neurological side effects of metoclopramide:
61
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Dyskinesia consists in rapid, involuntary and repetitive movements of the face, torso, limbs and
respiratory muscles. This is an extrapyramidal side effect that can have an early or a late onset (tardive
dyskinesia) and is irreversible in about 6% of cases (4). Metoclopramide induced tardive dyskinesia has
an incidence lower than 1%. The favoring factors for this condition are the long term use, old age,
female gender, diabetes, preexisting abnormal movements, organic cerebral lesions and psychic
disorders (3).
A study on a group of 51 hospitalized patients, all under metoclopramide therapy for at least 30
days, demonstrated that 27% of them developed tardive dyskinesia symptoms, compared to only 12%
that developed the same symptoms in the control group (9).
Dystonia consists in involuntary muscle contractions of the torso and neck (torticollis,
opisthotonus), limbs, tongue, face, eyes, laryngeal spasm, pharyngeal dysphagia, hoarseness and
oculogyric crisis. The incidence of metoclopramide induced acute dystonia is between 0.2% and 6%,
especially occurring in women after intravenous administration of relative high doses. These
manifestations usually can be observed in the first 24-48 hours after the initiation of metoclopramide
therapy (3, 4, 10).
Akathisia is an extrapyramidal disorder characterized by a feeling of unease, anxiety, permanent
and meaningless movements of the extremities or of the entire body. The incidence of metoclopramide
induced akathisia is between 10% and 25%, it can have various levels of severity and it can be prevented
by reducing the speed of metoclopramide intravenous injection. Benzodiazepines, β-blockers, opioids,
α2 presynaptic agonists and anticholinergic drugs can be used for treating this disorder (3, 4, 11).
Parkinsonism is characterized by tremors, bradykinesia, muscle rigidity and posture instability.
Long term use of metoclopramide, old age, female gender, diabetes and multiple drug abuse are favoring
factors for metoclopramide induced parkinsonism. Patients using metoclopramide are 3 times more
likely to require antiparkinson treatment than patients that are not using this antiemetic (12).
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Out of 479 reported cases of metoclopramide induced extrapyramidal effects in the UK over a
period of 15 years, 455 were acute dystonia reports, 20 were parkinsonism reports, and 4 were tardive
dyskinesia reports (10).
Constant reports regarding metoclopramide extrapyramidal side effects were registered all over
the world ever since this drug was first introduced in therapy up to the present day. This fact prompted
the development of a standardized quantification system in order to better understand the clinical
manifestations of extrapyramidal side effects. Thus the Abnormal Involuntary Movement Scale (AIMS)
was created as a tool for cataloging this type of manifestations both from a qualitative and a quantitative
point of view. With the help of AIMS, several irregular movements were characterized in 7 distinct areas
of the body, especially the face, mouth, extremities and torso. The AIMS score is now a useful tool that
allows a better management of extrapyramidal disorders (4).
The results of our study, generally confirm the known data described by medical literature
regarding metoclopramide neurological side effects, but also reveal some elements that are characteristic
to Romanian patients. Thus, the study shows that metoclopramide therapy was initiated based on a
written medical prescription in only 67.5% of cases. This is a relatively low percentage compared to the
one observed in western countries where more than 90% of patients start administering drugs only after
getting a written medical prescription. Our study also highlights the fact that 7.8% of patients have
chosen to self administer metoclopramide based on their own knowledge about the drug or on the
recommendation of unauthorized persons. In other countries less than 2% of patients do the same (13).
Regarding side effects, a little over a quarter of all patients (25.4%) reported experiencing them.
72.83% of these patients rated the side effect intensity as being low or moderate.
Analyzing the use of multiple drugs at the same time, we noted that more than half of all patients
(57.6%) reported using at least one other drug while under treatment with metoclopramide. 32.64%
indicated omeprazole as being that drug. When correlating the side effect reports with multiple drug use
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reports, we calculated that 38.98% of patients that reported side effects had taken metoclopramide at the
same time with omeprazole. This situation can be explained by the fact that omeprazole is a known
CYP2C19 and CYP3A4 inhibitor, thus determining a relative overdosing of metoclopramide, when the 2
drugs are used at the same time. A similar phenomenon occurs when metoclopramide is used
simultaneously with fluoxetine or paroxetine, as the 2 antidepressants are strong CYP2D6 inhibitors and
can also determine a relative overdosing of metoclopramide (14), which explains why these patients
reported more intense side effects. An additional explanation for a higher intensity of side effects in this
particular case may also be related to a 5HT4 receptors agonist mechanism that metoclopramide is
reported to have, thus favoring the onset of a serotoninergic syndrome (15).
The sedation induced by 1st generation antihistaminic drugs (H1-blockers) was significantly
enhanced during metoclopramide therapy in 7 patients. They reported intense daytime sleepiness and
increased time reaction to external stimuli, which confirm the CNS inhibition effect of metoclopramide,
especially when the nervous tonus is already depressed.
Symptoms more or less intense, characteristic to the malignant neuroleptic syndrome were
described by a patient under treatment with the incisive neuroleptic drug haloperidol and by another one
under treatment with the sedative neuroleptic agent chlorpromazine. These symptoms manifested
themselves 12 hours or more after initiating metoclopramide therapy and can be explained by the
synergism of addition that occurs between the antiemetic and the antipsychotic drugs, both having an
antidopaminergic mechanism.
The onset of a convulsive episode more intense than usual, reported by 2 epileptic patients under
treatment with carbamazepine, while taking metoclopramide at the same time, can be explained by the
gastroprokinetic effect of this drug that accelerates the intestinal transit, thus reducing the absorption rate
of the antiepileptic.
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Conclusions
The current study underlines the importance of pharmacovigilence in identifying drug side
effects and their favoring factors (multiple drug use, noncompliance, self medication). Our results
confirm the data described by medical literature regarding metoclopramide neurological side effects.
The relatively low incidence of side effects we observed proves that the benefit/risk ratio of
metoclopramide continues to be a positive one. However closer monitoring of pharmacokinetic and
pharmacodynamic interactions is absolutely necessary in order to prevent the onset of unwanted effects,
especially in a complex pathological context that requires multiple drug use.
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